This study is currently not recruiting new participants. Add it to your favourites and check back later.
Clinical Trial

Treatment of Metastatic Non-Small Cell Lung Carcinoma

Study Description

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiotherapy (SABR) for metastatic NSCLC.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Pembrolizumab

Pembrolizumab

Radiation - Radiotherapy (SABR)

Radiotherapy

Additional Information

Official Study Title

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Clinical Trial ID

NCT03307759

ParticipAid ID

neg09a